The above article, published online on 4 March 2020 on Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal's Editor‐in‐Chief, Masanori Hatakeyama, the Japanese Cancer Association and John Wiley & Sons Australia, Ltd following concerns raised by a third party about figures within the article. During the journal's investigation into the concerns raised, the authors were not able to provide comprehensive original data for the relevant figures. Accordingly, the editors consider that the results in the published article are unreliable and do not sufficiently support the conclusions. The following authors of the article have stated that they were unaware of its publication: Shu‐Zhong Cui, Zi‐Ying Lei, Tian‐Pei Guan, Hao‐Wu Jiang.
. 2023 Dec 11;115(1):325. doi: 10.1111/cas.16018
Retraction: Cui S‐Z, Lei Z‐Y, Guan T–P, et al. Targeting USP1‐dependent KDM4A protein stability as a potential prostate cancer therapy. Cancer Science. 2020; 111: 1567–1581. https://doi.org/10.1111/cas.14375
Collection date 2024 Jan.
© 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
PMCID: PMC10823274 PMID: 38078665
This retracts the article "Targeting USP1‐dependent KDM4A protein stability as a potential prostate cancer therapy" in volume 111 on page 1567.
This article has been corrected. See Cancer Sci. 2024 Jun 2;115(7):2486.